For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Quest Diagnostics, Inc (NYSE: DGX) closed the day trading at $179.76 down -0.33% from the previous closing price of $180.36. In other words, the price has decreased by -$0.33 from its previous closing price. On the day, 0.58 million shares were traded. DGX stock price reached its highest trading level at $180.89 during the session, while it also had its lowest trading level at $179.46.
Ratios:
For a better understanding of DGX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 63.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.42. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.09. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
Citigroup Downgraded its Buy to Neutral on March 04, 2025, while the target price for the stock was maintained at $185.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’25 when Plewman Patrick sold 1,975 shares for $185.00 per share. The transaction valued at 365,375 led to the insider holds 15,269 shares of the business.
Plewman Patrick sold 4,532 shares of DGX for $829,356 on Aug 19 ’25. The SVP for Diagnostic Services now owns 17,244 shares after completing the transaction at $183.00 per share. On Aug 21 ’25, another insider, Plewman Patrick, who serves as the Officer of the company, bought 1,975 shares for $185.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 20101302272 and an Enterprise Value of 26284382208. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.50, and their Forward P/E ratio for the next fiscal year is 17.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91 while its Price-to-Book (P/B) ratio in mrq is 2.79. Its current Enterprise Value per Revenue stands at 2.498 whereas that against EBITDA is 12.772.
Stock Price History:
The Beta on a monthly basis for DGX is 0.54, which has changed by 0.15061128 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $185.62, while it has fallen to a 52-week low of $146.17. The 50-Day Moving Average of the stock is 2.70%, while the 200-Day Moving Average is calculated to be 6.98%.
Shares Statistics:
Over the past 3-months, DGX traded about 1.02M shares per day on average, while over the past 10 days, DGX traded about 845800 shares per day. A total of 112.00M shares are outstanding, with a floating share count of 111.28M. Insiders hold about 0.49% of the company’s shares, while institutions hold 98.42% stake in the company. Shares short for DGX as of 1755216000 were 4031308 with a Short Ratio of 3.93, compared to 1752537600 on 4575330. Therefore, it implies a Short% of Shares Outstanding of 4031308 and a Short% of Float of 4.1100003.
Dividends & Splits
DGX’s forward annual dividend rate is 3.10, up from 3.1 a year ago. Against a Trailing Annual Dividend Yield of 0.017187847The stock’s 5-year Average Dividend Yield is 1.87. The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-07-07 with an ex-dividend date of 2025-10-03. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 14.0 analysts. The consensus estimate for the next quarter is $2.42, with high estimates of $2.5 and low estimates of $2.35.
Analysts are recommending an EPS of between $9.81 and $9.67 for the fiscal current year, implying an average EPS of $9.75. EPS for the following year is $10.36, with 17.0 analysts recommending between $10.69 and $9.8.
Revenue Estimates
12 analysts predict $2.73B in revenue for the current quarter. It ranges from a high estimate of $2.76B to a low estimate of $2.71B. As of the current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.49BFor the next quarter, 12 analysts are estimating revenue of $2.72B. There is a high estimate of $2.74B for the next quarter, whereas the lowest estimate is $2.69B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $10.93B, while the lowest revenue estimate was $10.82B, resulting in an average revenue estimate of $10.86B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.24B in the next fiscal year. The high estimate is $11.38B and the low estimate is $11.12B.
